NC
BCRX icon

NinePointTwo Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

NinePointTwo Capital’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-17,174
Closed -$120K – 260
2023
Q2 		$120K Hold
17,174
– – 0.05% 228
2023
Q1 		$143K Hold
17,174
– – 0.05% 245
2022
Q4 		$197K Buy
+17,174
New +$214K 0.08% 124

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

NinePointTwo Capital's BCRX Position: Q3 2023 in Review

NinePointTwo Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2023, closing a stake of 17,174 shares — an estimated $120K sold.

NinePointTwo Capital first reported a position in BCRX in Q4 2022 and held it in 3 quarters. The position peaked at $197K in Q4 2022. 233 funds tracked by Wall St. Rank hold BCRX as of Q3 2023.

  • NinePointTwo Capital reported no remaining BioCryst Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • NinePointTwo Capital sold 17,174 BioCryst Pharmaceuticals shares in Q3 2023, an estimated $120K.
  • NinePointTwo Capital first reported a position in BioCryst Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • NinePointTwo Capital's BioCryst Pharmaceuticals position peaked at $197K in Q4 2022.
  • 233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2023.

Based on NinePointTwo Capital's 13F filing for Q3 2023, filed 14 Nov 2023.